AI startup Bioptimus, founded by former Google employees, has recently secured $35 million in funding to accelerate innovation in the biomedical field using artificial intelligence technology.
The company, led by CEO Vert, aims to leverage AI to advance research in life sciences and biology by analyzing vast amounts of scientific data. Unlike traditional text-based AI models, Bioptimus will focus on utilizing scientific research data from various sources, including public databases and research institutions.
By building foundational models tailored to scientific data, Bioptimus plans to explore applications such as developing new bio proteins for medical treatments and enhancing data analysis for cancer research. The startup’s funding round was led by Sofinnova Partners, with contributions from other prominent investors like Owkin and tech entrepreneur Xavier Niel.
Vert expressed optimism about the fundraising process, emphasizing the industry’s readiness for AI-driven innovation. The company intends to use the funds to enhance computational capabilities, access more data for model training, and expand its team to around 20 members by the end of the year.
Bioptimus’ strategic approach to leveraging AI in biomedical research has garnered significant interest from investors and industry experts, positioning the startup for future growth and impact in the healthcare sector.
